Novartis antibiotic retreat doesn’t stop Sandoz buying GSK d...

Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalospor

1 week to SMi’s Superbugs & Superdrugs - REMOTE ACCESS ONLY

1 week to Superbugs & Superdrugs - REMOTE ACCESS ONLY

Interview with Martin Everett speaker at SMi’s Superbugs & S...

Interview with Martin Everett speaker at Superbugs

Still too little progress on antibiotic resistance, says O’N...

FDA okays Nabriva’s novel antibiotic Xenleta for pneumonia

Who will pay the price for inaction on superbugs?

While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts to convince pharma to invest in new antibiotics have so far been